Due diligence/ Investment  screening

This project is to initiate a thorough investment research on Ambulatory Surgery Centers (ASCs) and related MSOs.  We are seeking to segment the market opportunity for a cash-pay, outpatient surgical services business sold to cash-paying patient, self-insured employees and pooled risk groups.   The company is in development stage and has two operating rooms under a 10 year lease (19,108 sq. ft. space) in Colorado in preparing to open in first and second quarter of 2024 and expects to reach capacity by year end. Two additional centers are scheduled for Q1 2025. 

The company is in discussions with over 25 physicians in Denver including: Anesthesiologists, Orthopedic Surgery, Spine (Neurosurgery), ENT (Ears, Nose and Throat), General (Hernia, Gall Bladder, Appendectomy, Etc.), Ankles and Feet (Podiatrist), and Plastic Surgery. The Company is continuing to recruit within these specialties, as well as Gynecology, Gastroenterologist, Oncology, Vascular Surgery, and Urology. The Company has began surgeries and has engaged a marketing firm to build its website and direct marketing program. It has also engaged business development service providers that sale to self-insured employers, third party administrators in the Denver market.  

Among the MSO's services are: sales and marketing, leasing and subleasing surgery rooms and equipment, and related support services to company linked ASCs.    The Company is aligned with a 25+ years old successful regional cash pay ASC it aims to update and scale with modern technology and efficiency to expand it nationally.   Central to the Company's strategy is "Direct Specialty Care" (DSC) designed to remove the tremendous insurance processing costs in the industry that account for 40-50% of the total cost of insurance pay models. This allows the Company to compete for some of the best surgeons in the market in the traditional hospital models by offering better pay, reduced paperwork and delayed payments.   The company believes it can offer certain outpatient surgeries for American Society of Anesthesiologists (ASA) Level I and II patients (voluntary surgeries for non-acuity patients) with fully transparent pricing and at an average cost of about 40% what the local hospitals charge. The company's plan through 2029 is to finalize 12 operating rooms in 3 locations that perform about 6,000 of the 23 million surgeries performed in ASCs. 

We are in the initial stage of investment analysis to determine the investment potential, risks and the urgency of the problem that enable customer acquisition. We're looking for industry analysts, operators and investors who understand this market to support our initial screening and qualification with a potential to be part of the deal to the extent the company qualifies our return target.